NO309456B1 - Anvendelse av et östrogen og et antiprogestin for fremstilling av et medikament for hormonbehandling og kit inneholdende et östrogen og et antiprogestin - Google Patents
Anvendelse av et östrogen og et antiprogestin for fremstilling av et medikament for hormonbehandling og kit inneholdende et östrogen og et antiprogestin Download PDFInfo
- Publication number
- NO309456B1 NO309456B1 NO953243A NO953243A NO309456B1 NO 309456 B1 NO309456 B1 NO 309456B1 NO 953243 A NO953243 A NO 953243A NO 953243 A NO953243 A NO 953243A NO 309456 B1 NO309456 B1 NO 309456B1
- Authority
- NO
- Norway
- Prior art keywords
- antiprogestin
- estrogen
- administration
- amount
- use according
- Prior art date
Links
- 239000000262 estrogen Substances 0.000 title claims abstract description 63
- 229940011871 estrogen Drugs 0.000 title claims abstract description 62
- 230000000708 anti-progestin effect Effects 0.000 title claims abstract description 59
- 239000003418 antiprogestin Substances 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000001794 hormone therapy Methods 0.000 title 1
- 238000002657 hormone replacement therapy Methods 0.000 claims abstract description 12
- 230000002357 endometrial effect Effects 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 11
- 239000000583 progesterone congener Substances 0.000 claims description 11
- 206010001928 Amenorrhoea Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 201000000736 Amenorrhea Diseases 0.000 claims description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 6
- 231100000540 amenorrhea Toxicity 0.000 claims description 6
- 210000004696 endometrium Anatomy 0.000 claims description 5
- 230000005906 menstruation Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229960003248 mifepristone Drugs 0.000 claims description 3
- 102000003998 progesterone receptors Human genes 0.000 claims 2
- 108090000468 progesterone receptors Proteins 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 description 19
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000009164 estrogen replacement therapy Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000000737 periodic effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010047998 Withdrawal bleed Diseases 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010041541 Spinal compression fracture Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000010036 cardiovascular benefit Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229950001701 lilopristone Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Dental Preparations (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/023,692 US5468736A (en) | 1993-02-25 | 1993-02-25 | Hormone replacement therapy |
| PCT/US1994/001815 WO1994018983A1 (en) | 1993-02-25 | 1994-02-18 | Hormone replacement therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953243D0 NO953243D0 (no) | 1995-08-17 |
| NO953243L NO953243L (no) | 1995-08-17 |
| NO309456B1 true NO309456B1 (no) | 2001-02-05 |
Family
ID=21816657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO953243A NO309456B1 (no) | 1993-02-25 | 1995-08-17 | Anvendelse av et östrogen og et antiprogestin for fremstilling av et medikament for hormonbehandling og kit inneholdende et östrogen og et antiprogestin |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5468736A (hu) |
| EP (1) | EP0686037B1 (hu) |
| JP (1) | JP3441459B2 (hu) |
| KR (1) | KR100248857B1 (hu) |
| AT (1) | ATE202281T1 (hu) |
| AU (1) | AU680239B2 (hu) |
| BG (1) | BG62383B1 (hu) |
| BR (1) | BR9406667A (hu) |
| CA (1) | CA2157003C (hu) |
| CZ (1) | CZ290562B6 (hu) |
| DE (1) | DE69427529T2 (hu) |
| DK (1) | DK0686037T3 (hu) |
| ES (1) | ES2159552T3 (hu) |
| FI (1) | FI953926A (hu) |
| GR (1) | GR3036649T3 (hu) |
| HU (1) | HU221169B1 (hu) |
| NO (1) | NO309456B1 (hu) |
| NZ (1) | NZ262657A (hu) |
| PL (1) | PL176796B1 (hu) |
| PT (1) | PT686037E (hu) |
| RO (1) | RO115115B1 (hu) |
| RU (1) | RU2139056C1 (hu) |
| SK (1) | SK282921B6 (hu) |
| UA (1) | UA43842C2 (hu) |
| WO (1) | WO1994018983A1 (hu) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| US7704983B1 (en) | 1992-03-02 | 2010-04-27 | Eastern Virginia Medical School | Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception |
| US6407082B1 (en) | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
| AU5942700A (en) * | 1996-03-11 | 2000-11-30 | Schering Aktiengesellschaft | Sequential estrogen/progestrone antagonist combination for hormone replacement theapy |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US20060014728A1 (en) * | 1996-11-21 | 2006-01-19 | Kristof Chwalisz | Hormone replacement therapy |
| US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| IL148417A0 (en) * | 1999-08-31 | 2002-09-12 | Jenapharm Gmbh | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| US7629334B1 (en) | 1999-08-31 | 2009-12-08 | Bayer Schering Pharma Aktiengesellschaft | Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) |
| US6432643B1 (en) | 1999-10-22 | 2002-08-13 | Duke University | Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| PT1390040E (pt) * | 2001-05-18 | 2007-04-30 | Pantarhei Bioscience Bv | Composição farmacêutica para ser utilizado na terapia hormonal de substituição. |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US7871995B2 (en) * | 2001-05-23 | 2011-01-18 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| DK1390042T3 (da) * | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| WO2003018026A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| US8026228B2 (en) * | 2001-11-15 | 2011-09-27 | Pantarhei Bioscience B.V. | Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| DE10206089A1 (de) | 2002-02-13 | 2002-08-14 | Zimmer Ag | Bersteinsatz |
| CN1691947B (zh) * | 2002-06-11 | 2011-11-23 | 潘塔希生物科学股份有限公司 | 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物 |
| CA2489270C (en) * | 2002-06-11 | 2012-08-07 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| ES2299730T3 (es) * | 2002-07-12 | 2008-06-01 | Pantarhei Bioscience B.V. | Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer. |
| WO2004037269A1 (en) * | 2002-10-23 | 2004-05-06 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| SI1624878T1 (sl) * | 2003-05-22 | 2007-02-28 | Pantarhei Bioscience Bv | Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine |
| MX343130B (es) * | 2006-10-24 | 2016-10-26 | Repros Therapeutics Inc | Composiciones y métodos para suprimir la proliferación endometrial. |
| CN101583363B (zh) * | 2007-01-08 | 2013-08-21 | 潘塔希生物科学股份有限公司 | 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒 |
| US20080293683A1 (en) * | 2007-05-24 | 2008-11-27 | University Of Kansas Medical Center | Hormone Replacement Therapy |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2016090139A1 (en) * | 2014-12-03 | 2016-06-09 | Evestra, Inc. | Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer |
| KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890356A (en) * | 1973-03-26 | 1975-06-17 | Richardson Merrell Inc | 7-Alkyl-{66 {hu 3,5{b -steroids |
| US3928398A (en) * | 1973-11-01 | 1975-12-23 | Richardson Merrell Inc | Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol |
| US4416822A (en) * | 1982-07-09 | 1983-11-22 | The Upjohn Company | 17β-Difluoromethyl steroids |
| IL68222A (en) * | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
| AU572589B2 (en) * | 1983-12-14 | 1988-05-12 | Upjohn Company, The | 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids |
| MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
-
1993
- 1993-02-25 US US08/023,692 patent/US5468736A/en not_active Expired - Lifetime
-
1994
- 1994-02-18 JP JP51919494A patent/JP3441459B2/ja not_active Expired - Lifetime
- 1994-02-18 CZ CZ19952048A patent/CZ290562B6/cs not_active IP Right Cessation
- 1994-02-18 AT AT94909721T patent/ATE202281T1/de active
- 1994-02-18 ES ES94909721T patent/ES2159552T3/es not_active Expired - Lifetime
- 1994-02-18 EP EP94909721A patent/EP0686037B1/en not_active Expired - Lifetime
- 1994-02-18 KR KR1019950703613A patent/KR100248857B1/ko not_active IP Right Cessation
- 1994-02-18 RO RO95-01510A patent/RO115115B1/ro unknown
- 1994-02-18 AU AU62454/94A patent/AU680239B2/en not_active Expired
- 1994-02-18 PL PL94310660A patent/PL176796B1/pl unknown
- 1994-02-18 PT PT94909721T patent/PT686037E/pt unknown
- 1994-02-18 RU RU95118436/14A patent/RU2139056C1/ru active
- 1994-02-18 HU HU9502306A patent/HU221169B1/hu unknown
- 1994-02-18 SK SK1049-95A patent/SK282921B6/sk not_active IP Right Cessation
- 1994-02-18 DE DE69427529T patent/DE69427529T2/de not_active Expired - Lifetime
- 1994-02-18 NZ NZ262657A patent/NZ262657A/en not_active IP Right Cessation
- 1994-02-18 CA CA002157003A patent/CA2157003C/en not_active Expired - Lifetime
- 1994-02-18 DK DK94909721T patent/DK0686037T3/da active
- 1994-02-18 WO PCT/US1994/001815 patent/WO1994018983A1/en active IP Right Grant
- 1994-02-18 BR BR9406667A patent/BR9406667A/pt not_active Application Discontinuation
- 1994-02-18 UA UA95083916A patent/UA43842C2/uk unknown
-
1995
- 1995-08-17 NO NO953243A patent/NO309456B1/no not_active IP Right Cessation
- 1995-08-22 FI FI953926A patent/FI953926A/fi not_active Application Discontinuation
- 1995-08-23 BG BG99880A patent/BG62383B1/bg unknown
-
2001
- 2001-09-18 GR GR20010401507T patent/GR3036649T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309456B1 (no) | Anvendelse av et östrogen og et antiprogestin for fremstilling av et medikament for hormonbehandling og kit inneholdende et östrogen og et antiprogestin | |
| US5108995A (en) | Hormone preparation and method | |
| US5585370A (en) | Hormone preparation and method | |
| EP0559240B1 (en) | Contraceptive packages containing oestrogen and progestin | |
| Session et al. | Current concepts in estrogen replacement therapy in the menopause | |
| JP2965160B2 (ja) | 避妊を達成する組成物 | |
| US5256421A (en) | Hormone preparation and method | |
| JPS61178917A (ja) | 抗エストロゲンと担体よりなる組成物の製法 | |
| MXPA01009813A (es) | Terapia interrumpida de reemplazo de hormonas con dosis bajas de estrogeno. | |
| Batur et al. | Update on contraception: benefits and risks of the new formulations | |
| Pasquale | Rationale for a triphasic oral contraceptive | |
| US11376263B2 (en) | Cyproterone acetate compositions and uses thereof | |
| DK174181B1 (da) | Farmaceutisk præparat til hormonbehandling | |
| Joshi et al. | 238. Interaction of an oral contraceptive with metronidazole and ampicillin therapy | |
| Mandlekar et al. | 236. Long-acting systemic steroids in contraceptive practice | |
| Datta et al. | 239. Studies on the nature and mode of action of centchroman in rats | |
| Jha et al. | 237. Hormone levels and endometrial histology in women bearing a norethindrone acatete releasing intrauterine contraceptive device | |
| IE84449B1 (en) | Contraceptive packages containing oestrogen and progestin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |